{"id":"65d4f9a0-9c6a-5422-a237-5c05186c993a","stable_key":"4910e17b-aaec-52cd-b9e5-caca85d817ee:red-yeast-rice-becker-tolerability","predicate":"does_not_significantly_change_tested","statement":"Pain, CPK and liver-enzyme results did not differ significantly between groups in the 24-week trial.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"51539a71-5a4a-5067-92a2-ab0b703cf167","mechanism_event_label":"The trial retained tolerability outcomes as well as LDL changes.","subject":{"id":"0fb5e8c6-6cfc-514e-aaf5-a2eb3f8a0b23","slug":"ryr-becker-2009-preparation","display_name":"Red yeast rice preparation in the Becker 2009 trial","entity_type_key":"chemical_species"},"object":{"id":"522d0084-b784-5937-a831-c5bb20cc00e8","slug":"human-becker-ryr-pain-ck","display_name":"Pain and creatine-kinase endpoints in the Becker red yeast rice trial","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"51539a71-5a4a-5067-92a2-ab0b703cf167","stable_key":"4910e17b-aaec-52cd-b9e5-caca85d817ee:red-yeast-rice-becker-tolerability-event","event_type":"observed_relationship","label":"The trial retained tolerability outcomes as well as LDL changes.","description":"Pain, CPK and liver-enzyme results did not differ significantly between groups in the 24-week trial.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"0fb5e8c6-6cfc-514e-aaf5-a2eb3f8a0b23","slug":"ryr-becker-2009-preparation","display_name":"Red yeast rice preparation in the Becker 2009 trial","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"522d0084-b784-5937-a831-c5bb20cc00e8","slug":"human-becker-ryr-pain-ck","display_name":"Pain and creatine-kinase endpoints in the Becker red yeast rice trial","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"62 previously statin-intolerant participants.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Insufficient to exclude rare muscle or liver injury, or establish that all red yeast rice is safer than statins.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Red yeast rice collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"red-yeast-rice","display_name":"Red yeast rice","entity_type_key":"chemical_species"}},{"dimension":"plain_language","value_text":"The trial retained tolerability outcomes as well as LDL changes.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[19528562] Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19528562/ · DOI 10.7326/0003-4819-150-12-200906160-00006","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"3afd9191-d164-5576-9847-1e750b6859f4","evidence_kind":"source_excerpt","locator":"Lines 348-354","start_line":348,"end_line":354,"excerpt":"## red-yeast-rice-becker-tolerability\nThe trial retained tolerability outcomes as well as LDL changes.\nPain, CPK and liver-enzyme results did not differ significantly between groups in the 24-week trial.\nModel: 62 previously statin-intolerant participants.\nLimitations: Insufficient to exclude rare muscle or liver injury, or establish that all red yeast rice is safer than statins.\nEvidence access: Primary abstract\n[19528562] Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19528562/ · DOI 10.7326/0003-4819-150-12-200906160-00006","model_system":"62 previously statin-intolerant participants.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"261a12bc-3d00-52a4-a5ec-70e174390596","stable_key":"import-4910e17b-aaec-52cd-b9e5-caca85d817ee","title":"Red yeast rice: constituents, mevalonate, CoQ and product-specific interactions (2026-09-20)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"271bbcecaaacc76ad4d06718ae592dc6a1b33e3e459adfdd36cbd0ac5f09c0f6","revision_id":"9c30956c-206c-5c49-ae42-81b070088e26","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}